The stock of Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) is a huge mover today! About 271,428 shares traded hands or 31.15% up from the average. Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) has declined 46.80% since March 8, 2016 and is downtrending. It has underperformed by 56.12% the S&P500.
The move comes after 8 months negative chart setup for the $155.10 million company. It was reported on Oct, 11 by Barchart.com. We have $4.46 PT which if reached, will make NASDAQ:NVIV worth $15.51 million less.
Analysts await Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) to report earnings on November, 2. They expect $-0.22 EPS, 0.00% or $0.00 from last year’s $-0.22 per share. After $-0.18 actual EPS reported by Invivo Therapeutics Holdings Corp for the previous quarter, Wall Street now forecasts 22.22% negative EPS growth.
According to Zacks Investment Research, “InVivo Therapeutics Holdings Corp. operates as a medical device company focused on utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed as a result of traumatic spinal cord injury. The company intends to offer three products, including a biocompatible polymer scaffolding device to treat acute wound SCI; a biocompatible hydrogel for local controlled release of methylprednisolone to treat acute SCI; and a biocompatible polymer scaffolding device seeded with autologous hNSCs to treat acute and chronic SCI. InVivo Therapeutics Holdings Corp. is based in Cambridge, Massachusetts.”
More notable recent Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) news were published by: Marketwatch.com which released: “InVivo Therapeutics Holdings Corp.” on April 25, 2011, also Businesswire.com with their article: “InVivo Therapeutics Appoints Pamela Stahl as Chief Commercial Officer” published on August 11, 2016, Businesswire.com published: “InVivo Therapeutics Announces Bioengineered Neural Trailsâ„¢ Program for …” on December 02, 2015. More interesting news about Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) were released by: Businesswire.com and their article: “InVivo Therapeutics Holdings Corp. Announces Pricing of Public Offering of …” published on March 15, 2016 as well as 247Wallst.com‘s news article titled: “Why InVivo Therapeutics Soared” with publication date: March 07, 2016.
NVIV Company Profile
InVivo Therapeutics Holdings Corp., formerly Design Source, Inc., incorporated on April 2, 2003, is a research and clinical-stage biomaterials and biotechnology company. The Firm is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company’s approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury. It is also evaluating other technologies and therapeutics that may be complementary to its development of the Neuro-Spinal Scaffold implant. The Firm has a clinical development program for acute SCI and a preclinical development program for chronic SCI.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.